PMID- 37112884
OWN - NLM
STAT- MEDLINE
DCOM- 20230501
LR  - 20230501
IS  - 1999-4915 (Electronic)
IS  - 1999-4915 (Linking)
VI  - 15
IP  - 4
DP  - 2023 Mar 31
TI  - HLA Variation and SARS-CoV-2 Specific Antibody Response.
LID - 10.3390/v15040906 [doi]
LID - 906
AB  - Differences in SARS-CoV-2-specific immune responses have been observed between 
      individuals following natural infection or vaccination. In addition to already 
      known factors, such as age, sex, COVID-19 severity, comorbidity, vaccination 
      status, hybrid immunity, and duration of infection, inter-individual variations 
      in SARS-CoV-2 immune responses may, in part, be explained by structural 
      differences brought about by genetic variation in the human leukocyte antigen 
      (HLA) molecules responsible for the presentation of SARS-CoV-2 antigens to T 
      effector cells. While dendritic cells present peptides with HLA class I molecules 
      to CD8+ T cells to induce cytotoxic T lymphocyte responses (CTLs), they present 
      peptides with HLA class II molecules to T follicular helper cells to induce B 
      cell differentiation followed by memory B cell and plasma cell maturation. Plasma 
      cells then produce SARS-CoV-2-specific antibodies. Here, we review published data 
      linking HLA genetic variation or polymorphisms with differences in 
      SARS-CoV-2-specific antibody responses. While there is evidence that 
      heterogeneity in antibody response might be related to HLA variation, there are 
      conflicting findings due in part to differences in study designs. We provide 
      insight into why more research is needed in this area. Elucidating the genetic 
      basis of variability in the SARS-CoV-2 immune response will help to optimize 
      diagnostic tools and lead to the development of new vaccines and therapeutics 
      against SARS-CoV-2 and other infectious diseases.
FAU - Wolday, Dawit
AU  - Wolday D
AD  - Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, 
      ON M5G 1Z5, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON M5G 1Z5, 
      Canada.
FAU - Fung, Chun Yiu Jordan
AU  - Fung CYJ
AD  - Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, 
      ON M5G 1Z5, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON M5G 1Z5, 
      Canada.
FAU - Morgan, Gregory
AU  - Morgan G
AUID- ORCID: 0000-0001-7027-5753
AD  - Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, 
      ON M5G 1Z5, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON M5G 1Z5, 
      Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, ON M5G 1Z5, Canada.
FAU - Casalino, Selina
AU  - Casalino S
AD  - Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, 
      ON M5G 1Z5, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON M5G 1Z5, 
      Canada.
FAU - Frangione, Erika
AU  - Frangione E
AD  - Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, 
      ON M5G 1Z5, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON M5G 1Z5, 
      Canada.
FAU - Taher, Jennifer
AU  - Taher J
AUID- ORCID: 0000-0001-9377-968X
AD  - Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, 
      ON M5G 1Z5, Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, ON M5G 1Z5, Canada.
FAU - Lerner-Ellis, Jordan P
AU  - Lerner-Ellis JP
AUID- ORCID: 0000-0003-3685-5679
AD  - Pathology and Laboratory Medicine, Mount Sinai Hospital, Sinai Health, Toronto, 
      ON M5G 1Z5, Canada.
AD  - Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, ON M5G 1Z5, 
      Canada.
AD  - Department of Laboratory Medicine and Pathobiology, University of Toronto, 
      Toronto, ON M5G 1Z5, Canada.
LA  - eng
GR  - VR4-172753/CIHR/Canada
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230331
PL  - Switzerland
TA  - Viruses
JT  - Viruses
JID - 101509722
RN  - 0 (Histocompatibility Antigens Class I)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens)
RN  - 0 (Peptides)
RN  - 0 (Histocompatibility Antigens Class II)
SB  - IM
MH  - Humans
MH  - *SARS-CoV-2/genetics
MH  - *COVID-19
MH  - Antibody Formation
MH  - Histocompatibility Antigens Class I
MH  - HLA Antigens/genetics
MH  - Histocompatibility Antigens
MH  - CD8-Positive T-Lymphocytes
MH  - Peptides
MH  - Histocompatibility Antigens Class II
PMC - PMC10143129
OTO - NOTNLM
OT  - COVID-19
OT  - HLA
OT  - MHC
OT  - SARS-CoV-2
OT  - antibody
OT  - genomics
OT  - immunoglobulin
OT  - polymorphism
COIS- The authors declare no conflict of interest.
EDAT- 2023/04/28 06:42
MHDA- 2023/05/01 06:42
PMCR- 2023/03/31
CRDT- 2023/04/28 01:54
PHST- 2023/03/15 00:00 [received]
PHST- 2023/03/29 00:00 [revised]
PHST- 2023/03/29 00:00 [accepted]
PHST- 2023/05/01 06:42 [medline]
PHST- 2023/04/28 06:42 [pubmed]
PHST- 2023/04/28 01:54 [entrez]
PHST- 2023/03/31 00:00 [pmc-release]
AID - v15040906 [pii]
AID - viruses-15-00906 [pii]
AID - 10.3390/v15040906 [doi]
PST - epublish
SO  - Viruses. 2023 Mar 31;15(4):906. doi: 10.3390/v15040906.